Clinical Trial: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Study Status: Completed
Recruit Status: RECRUITING
Condition: Newly Diagnosed MGMT Unmethylated Glioblastoma
Study Type: INTERVENTIONAL
Official Title: Delivery of D2C7-IT and 2141-V11 Combination Immunotherapy in Residual Disease for Adult Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma and Perilymphatic Subcutaneous Injections of 2141-
Brief Summary:
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery, followed by later repeated injections of 2141-V11 in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adults newly diagnosed with a type of cancerous brain tumor called glioblastoma.The word…
Read more